Document is current

Article History

Received: 20 December 2024

Accepted: 30 April 2025

First Online: 20 May 2025

Declarations

:

: Antonio González-Martín declares grants or contracts from GSK, Roche, ISCiii, and AECC; consulting fees from Incyte, Pharmaand, Daichii, Alkermes, Amgen, AstraZeneca, Clovis, Genmab, GSK, HederaDX, Immunogen, Kartos, Karyopharm, Illumina, Mersana, MSD, Novartis, Novocure, Oncoinvent, PharmaMar, Roche, SOTIO, SUTRO, Seagen, Takeda, and Tubulis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Clovis, GSK, Immunogen, Mersana, MSD, Novocure, PharmaMar, Roche, Takeda, Seagen, and Zai Lab; and support for attending meetings and/or travel from AstraZeneca, Clovis, GSK, Immunogen, Mersana, MSD, Novocure, PharmaMar, Roche, and Takeda. Alejandro Gallego declares grants or contracts from GEICO and SEOM; consulting fees from GSK, MSD, AstraZeneca, and Clovis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, AstraZeneca, MSD, Clovis, and GSK; payment for expert testimony from GSK, MSD, AstraZeneca, and Clovis; support for attending meetings and/or travel from Roche, MSD, GSK, AstraZeneca, and PharmaMar; participation on a data safety monitoring board or advisory board from PharmaMar and GSK; and participation in a company sponsored speaker’s bureau from Roche, AstraZeneca, MSD, Clovis, and GSK. Yolanda García declares consulting fees from Roche, Astrazeneca, GSK, MSD, and Clovis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Astrazeneca, GSK, MSD, and Clovis; support for attending meetings and/or travel from Roche, GSK, and MSD; and participation on a data safety monitoring board or advisory board from Roche, GSK, and Astrazeneca. Eva Guerra declares consulting fees from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar, and Roche; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar, Roche, and Eisai; payment for expert testimony from AstraZeneca-MSD, GSK-Tesaro, PharmaMar, Roche, Pharma& and Eisai; support for attending meetings and/or travel from GSK; and participation on a data safety monitoring board or advisory board from AstraZeneca. Purificación Estévez-García declares grants or contracts from GSK; consulting fees from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai; support for attending meetings and/or travel from GSK, MSD, AstraZeneca, Clovis, and PharmaMar; and participation on a data safety monitoring board or advisory board from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai. Maria Pilar Barretina-Ginesta declares consulting fees from Astrazeneca, Clovis, GSK, MSD, PharmaMar, Pharmaand, Eisai, and Roche; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astrazeneca, Clovis, Eisai, GSK, MSD, Pharmamar, and Roche; support for attending meetings and/or travel from Astrazeneca, GSK, and MSD; and participation on a data safety monitoring board or advisory board from MSD. Pilar Borraz is a Roche Pharma employee. Maria Quindós-Varela, María Jesús Rubio, and Diego Soto de Prado-Otero declare that they have no conflicts of interest.

: The present study identified with the code ML40141 was approved by the Ethics Committee of Hospital Universitari Doctor Josep Trueta de Girona during the meeting held on the 17 July 2018. All patients provided informed consent to participate in the study. The study was performed in accordance with the Declaration of Helsinki (1964 and its later amendments).